Chronic Cigarette Smoke Exposure and its Impact on Muscle Signaling Pathways

The article evaluates skeletal muscle dysfunction in COPD patients, characterized by reduced muscle strength and endurance. Preclinical studies show that stimulating the sGC-cGMP pathway may prevent muscle mass loss and cigarette smoke-induced oxidative stress. The study evaluated the effect of cigarette smoke on biomarkers of muscle fatigue and the potential efficacy of an sGC stimulator in an animal model of COPD. Exposure to cigarette smoke led to weight loss and increased proteolytic markers of muscle atrophy in the gastrocnemius muscle. Treatment with an sGC stimulator resulted in a reduction in proteolytic markers, weight recovery, and increased cGMP levels. The study suggests that targeting sGC may be a beneficial therapeutic strategy for muscle alterations in COPD patients.